Despite Concerns Over Extrapolation, Bevacizumab Biosimilars Are Widely Used in mCRC
A review article investigating the use of bevacizumab biosimilars found that despite lingering concerns about their usage for extrapolated indications, bevacizumab biosimilars are regularly used in metastatic colorectal cancer (mCRC) even though clinical tests only evaluate them in patients with lung cancer.
Integrating Molecular Profiling of Adrenocortical Carcinoma Into Clinical Practice
Processes used to identify and understand genetic markers detailing the prognosis and responsiveness to therapy in adrenocortical carcinoma (ACC) face a number of implementation barriers, limiting the potential for individualized ACC management.